BerandaEBS • NYSE
add
Emergent Biosolutions Inc
$11,17
Setelah Jam Perdagangan Normal:(0,63%)+0,070
$11,24
Tutup: 28 Nov, 15.25.14 GMT-5 · USD · NYSE · Pernyataan Penyangkalan
Tutup sebelumnya
$11,05
Rentang hari
$11,11 - $11,31
Rentang tahun
$4,02 - $13,41
Kapitalisasi pasar
586,65 jt USD
Volume Rata-Rata
1,28 jt
Rasio P/E
8,61
Hasil dividen
-
Bursa utama
NYSE
Berita pasar
Keuangan
Laporan Laba Rugi
Pendapatan
Penghasilan bersih
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 231,10 jt | -21,34% |
Biaya operasional | 44,80 jt | -45,50% |
Penghasilan bersih | 51,20 jt | -55,40% |
Margin laba bersih | 22,15 | -43,31% |
Penghasilan per saham | 1,06 | -22,63% |
EBITDA | 110,30 jt | 2,41% |
Tarif pajak efektif | 11,11% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 245,50 jt | 63,78% |
Total aset | 1,46 M | -1,14% |
Total liabilitas | 878,50 jt | -9,38% |
Total ekuitas | 582,50 jt | — |
Saham yang beredar | 52,52 jt | — |
Harga terhadap nilai buku | 1,00 | — |
Tingkat pengembalian aset | 15,17% | — |
Tingkat pengembalian modal | 17,70% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Penghasilan bersih | 51,20 jt | -55,40% |
Kas dari operasi | -2,30 jt | -101,50% |
Kas dari investasi | -3,40 jt | -103,04% |
Kas dari pembiayaan | -15,90 jt | 91,18% |
Perubahan kas bersih | -21,80 jt | -125,53% |
Arus kas bebas | -7,44 jt | -104,63% |
Tentang
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid.
During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded. Wikipedia
Didirikan
5 Sep 1998
Kantor pusat
Karyawan
900
